| Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ... Nature genetics 50 (9), 1271-1281, 2018 | 549 | 2018 |
| Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer discovery 8 (2), 196-215, 2018 | 522 | 2018 |
| Response and acquired resistance to everolimus in anaplastic thyroid cancer N Wagle, BC Grabiner, EM Van Allen, A Amin-Mansour, A Taylor-Weiner, ... New England Journal of Medicine 371 (15), 1426-1433, 2014 | 373 | 2014 |
| Genomic analysis of metastatic cutaneous squamous cell carcinoma YY Li, GJ Hanna, AC Laga, RI Haddad, JH Lorch, PS Hammerman Clinical cancer research 21 (6), 1447-1456, 2015 | 305 | 2015 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial JD Schoenfeld, GJ Hanna, VY Jo, B Rawal, YH Chen, PS Catalano, ... JAMA oncology 6 (10), 1563-1570, 2020 | 286 | 2020 |
| Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial R Uppaluri, KM Campbell, AM Egloff, P Zolkind, ZL Skidmore, ... Clinical Cancer Research 26 (19), 5140-5152, 2020 | 285 | 2020 |
| Frameshift events predict anti–PD-1/L1 response in head and neck cancer GJ Hanna, P Lizotte, M Cavanaugh, FC Kuo, P Shivdasani, A Frieden, ... JCI insight 3 (4), e98811, 2018 | 263 | 2018 |
| Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States BA Mahal, PJ Catalano, RI Haddad, GJ Hanna, JI Kass, JD Schoenfeld, ... Cancer Epidemiology, Biomarkers & Prevention 28 (10), 1660-1667, 2019 | 204 | 2019 |
| Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: a cancer journal for clinicians 71 (2), 176-190, 2021 | 168 | 2021 |
| A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant N Murakami, P Mulvaney, M Danesh, A Abudayyeh, A Diab, ... Kidney international 100 (1), 196-205, 2021 | 158 | 2021 |
| Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer GJ Hanna, JG Supplee, Y Kuang, U Mahmood, CJ Lau, RI Haddad, ... Annals of Oncology 29 (9), 1980-1986, 2018 | 132 | 2018 |
| First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study SP D'Angelo, C Lebbé, L Mortier, AS Brohl, N Fazio, JJ Grob, N Prinzi, ... Journal for immunotherapy of cancer 9 (7), e002646, 2021 | 131 | 2021 |
| Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study GJ Hanna, NL Busaidy, NG Chau, LJ Wirth, JA Barletta, A Calles, ... Clinical cancer research 24 (7), 1546-1553, 2018 | 124 | 2018 |
| The use of hyperbaric oxygen for the prevention and management of osteoradionecrosis of the jaw: a Dana‐Farber/Brigham and Women’s Cancer Center multidisciplinary guideline A Sultan, GJ Hanna, DN Margalit, N Chau, LA Goguen, FM Marty, ... The oncologist 22 (3), 343-350, 2017 | 112 | 2017 |
| Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck GJ Hanna, A O'Neill, KY Shin, K Wong, VY Jo, CT Quinn, JM Cutler, ... Clinical Cancer Research 28 (3), 468-478, 2022 | 89 | 2022 |
| A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma U Mahmood, A Bang, YH Chen, RH Mak, JH Lorch, GJ Hanna, M Nishino, ... International Journal of Radiation Oncology* Biology* Physics 109 (1), 134-144, 2021 | 83 | 2021 |
| Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma BM Berger, GJ Hanna, MR Posner, EM Genden, J Lautersztain, SP Naber, ... Clinical Cancer Research 28 (19), 4292-4301, 2022 | 77 | 2022 |
| CIC‐NUTM1 fusion: A case which expands the spectrum of NUT‐rearranged epithelioid malignancies IM Schaefer, P Dal Cin, LM Landry, CDM Fletcher, GJ Hanna, CA French Genes, Chromosomes and Cancer 57 (9), 446-451, 2018 | 75 | 2018 |
| Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma GJ Hanna, SB Woo, YY Li, JA Barletta, PS Hammerman, JH Lorch International journal of oral and maxillofacial surgery 47 (5), 568-577, 2018 | 71 | 2018 |
| A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and … JH Lorch, JA Barletta, M Nehs, R Uppaluri, EK Alexander, RI Haddad, ... Journal of Clinical Oncology 38 (15_suppl), 6513-6513, 2020 | 64 | 2020 |
